TGF-β in Mice Ameliorates Experimental Autoimmune Encephalomyelitis in Regulating NK Cell Activity

Area of Science:

• Neuroimmunology
• Cellular and Molecular Immunology
• Autoimmune Diseases

Background:

• Multiple sclerosis (MS) is a central nervous system inflammatory and demyelinating disease.
• Experimental autoimmune encephalomyelitis (EAE) serves as the primary animal model for MS research.
• While T cell roles in MS/EAE are studied, other immune cells' functions remain less understood.

Purpose of the Study:

• To investigate the role of transforming growth factor-beta (TGF-β) in natural killer (NK) cell activity within the EAE model.
• To explore TGF-β's potential as a therapeutic agent for MS by modulating immune responses in EAE.

Main Methods:

• Induction of EAE in mice immunized with myelin oligodendrocyte glycoprotein (MOG) antigen.
• Administration of TGF-β to assess its impact on EAE clinical scores and inflammatory markers.
• Analysis of TGF-β expression, receptor levels, and downstream molecule activity in EAE.
• Evaluation of NK cell proliferation and expression of NK cell markers (e.g., NCR1) in response to TGF-β.

Main Results:

• TGF-β expression levels fluctuated during EAE, increasing at onset and decreasing at peak.
• TGF-β treatment significantly reduced EAE severity, lowering clinical scores and inflammatory cytokine production, including interleukin-17.
• TGF-β enhanced NK cell proliferation and increased the transcription of the NK cell marker NCR1 in both spleen and central nervous system tissues.

Conclusions:

• TGF-β confers protection against EAE in mice, primarily through the enhancement of NK cell activity.
• The findings highlight the therapeutic potential of TGF-β in managing MS by leveraging NK cell-mediated immune regulation.
• Targeting TGF-β and NK cells may offer a novel strategy for clinical therapy in multiple sclerosis.